



February 2, 2021

Canon Medical Systems Corporation  
% Ms. Janine F. Reyes  
Manager, Regulatory Affairs  
Canon Medical Systems USA, Inc.  
2441 Michelle Drive  
TUSTIN CA 92780

Re: K203553

Trade/Device Name: Vantage Galan 3T, MRT-3020, V7.0 with AiCE Reconstruction  
Processing Unit for MR

Regulation Number: 21 CFR 892.1000

Regulation Name: Magnetic Resonance Diagnostic Device

Regulatory Class: Class II

Product Code: LNH

Dated: December 2, 2020

Received: December 4, 2020

Dear Ms. Reyes:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm> identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part

801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see <https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products>); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems>.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (<https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance>) and CDRH Learn (<https://www.fda.gov/training-and-continuing-education/cdrh-learn>). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (<https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice>) for more information or contact DICE by email ([DICE@fda.hhs.gov](mailto:DICE@fda.hhs.gov)) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

For

Thalia T. Mills, Ph.D.  
Director  
Division of Radiological Health  
OHT7: Office of In Vitro Diagnostics  
and Radiological Health  
Office of Product Evaluation and Quality  
Center for Devices and Radiological Health

Enclosure

DEPARTMENT OF HEALTH AND HUMAN SERVICES  
Food and Drug AdministrationForm Approved: OMB No. 0910-0120  
Expiration Date: 06/30/2023  
See PRA Statement below.**Indications for Use**

510(k) Number (if known)

**K203553**

Device Name

Vantage Galan 3T, MRT-3020, V7.0 with AiCE Reconstruction Processing Unit for MR

Indications for Use (Describe)

Vantage Galan 3T systems are indicated for use as a diagnostic imaging modality that produces cross-sectional transaxial, coronal, sagittal, and oblique images that display anatomic structures of the head or body. Additionally, this system is capable of non-contrast enhanced imaging, such as MRA.

MRI (magnetic resonance imaging) images correspond to the spatial distribution of protons (hydrogen nuclei) that exhibit nuclear magnetic resonance (NMR). The NMR properties of body tissues and fluids are:

- Proton density (PD) (also called hydrogen density)
- Spin-lattice relaxation time (T1)
- Spin-spin relaxation time (T2)
- Flow dynamics
- Chemical Shift

Depending on the region of interest, contrast agents may be used. When interpreted by a trained physician, these images yield information that can be useful in diagnosis.

Type of Use (Select one or both, as applicable)

 Prescription Use (Part 21 CFR 801 Subpart D) Over-The-Counter Use (21 CFR 801 Subpart C)**CONTINUE ON A SEPARATE PAGE IF NEEDED.**

This section applies only to requirements of the Paperwork Reduction Act of 1995.

**\*DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.\***

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services  
Food and Drug Administration  
Office of Chief Information Officer  
Paperwork Reduction Act (PRA) Staff  
PRAStaff@fda.hhs.gov

*“An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number.”*

## 510(k) SUMMARY

This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of Safe Medical Device Act 1990 and 21 CFR § 807.92

### 1. CLASSIFICATION and DEVICE NAME

<b>Classification Name:</b>	<b>Magnetic Resonance Diagnostic Device</b>
<b>Regulation Number:</b>	<b>90-LNH (Per 21 CFR § 892.1000)</b>
<b>Trade Proprietary Name:</b>	<b>Vantage Galan 3T, MRT-3020, V7.0 with AiCE Reconstruction Processing Unit for MR</b>
<b>Model Number:</b>	<b>MRT-3020</b>

### 2. SUBMITTER'S NAME

Canon Medical Systems Corporation  
1385 Shimoishigami  
Otawara-Shi, Tochigi-ken, Japan 324-8550

### 3. OFFICIAL CORRESPONDENT

Naofumi Watanabe  
Senior Manager, Regulatory Affairs and Vigilance  
Canon Medical Systems Corporation

### 4. CONTACT PERSON, U.S. AGENT and ADDRESS

#### Contact Person

Janine F. Reyes  
Manager, Regulatory Affairs  
Canon Medical Systems USA, Inc.  
2441 Michelle Drive, Tustin, CA 92780  
Phone: (714) 669-7853  
Fax: (714) 730-1310  
E-mail: jfreyes@us.medical.canon

#### Official Correspondent/U.S. Agent

Paul Biggins  
Senior Director, Regulatory Affairs  
Canon Medical Systems USA, Inc.  
2441 Michelle Drive, Tustin, CA 92780  
Phone: (714) 730-7808  
Fax: (714) 730-1310  
E-mail: pbiggins@us.medical.canon



**5. MANUFACTURING SITE**

Canon Medical Systems Corporation  
1385 Shimoishigami  
Otawara-shi, Tochigi 324-8550, Japan

**6. ESTABLISHMENT REGISTRATION**

9614698

**7. DATE PREPARED**

December 2<sup>nd</sup>, 2020

**8. DEVICE NAME**

Vantage Galan 3T, MRT-3020, V7.0 with AiCE Reconstruction Processing Unit for MR

**9. TRADE NAME**

Vantage Galan 3T, MRT-3020, V7.0 with AiCE Reconstruction Processing Unit for MR

**10. CLASSIFICATION NAME**

Magnetic Resonance Diagnostic Device (MRDD)

**11. CLASSIFICATION PANEL**

Radiology

**12. DEVICE CLASSIFICATION**

Class II (per 21 CFR 892.1000, Magnetic Resonance Diagnostic Device)

**13. PRODUCT CODE**

90-LNH

**14. PREDICATE DEVICE**

**Predicate Device:** Vantage Galan 3T, MRT-3020, V6.0 with AiCE Reconstruction Processing Unit for MR (K192574)

	Subject Device	Predicate Device
<b>System</b>	Vantage Galan 3T, MRT-3020, V7.0 with AiCE Reconstruction Processing Unit for MR	Vantage Galan 3T, MRT-3020, V6.0 with AiCE Reconstruction Processing Unit for MR
<b>Marketed By</b>	Canon Medical Systems USA, Inc.	Canon Medical Systems USA, Inc.
<b>510(k) Number</b>	This Submission	K192574
<b>Clearance Date</b>		March 9, 2020

**15. REASON FOR SUBMISSION**

Modification of a cleared device

**16. SUBMISSION TYPE**

Traditional 510(k) Premarket Notification

## 17. DEVICE DESCRIPTION

The Vantage Galan (Model MRT-3020) is a 3 Tesla Magnetic Resonance Imaging (MRI) System, previously cleared under K192574. This system is based upon the technology and materials of previously marketed Canon Medical Systems MRI systems and is intended to acquire and display cross-sectional transaxial, coronal, sagittal, and oblique images of anatomic structures of the head or body.

## 18. SUMMARY OF CHANGE(S)

This submission is to report the following software changes:

- FASE 3D/FFE3D:
  - **Compressed SPEEDER 3D (Compressed Sensing 3D):** This application allows acceleration factors for shorter scan times or higher resolution in FASE3D and FFE3D in addition to FSE2D, imaging based upon the principle of compressed sensing in combination with parallel imaging.
- FE 3D:
  - **FI-Quant:** Data is acquired with several different TE and provides PDFF image, R2\* image, water image, fat image, in phase image and out of phase image (total 6 kind of images). Proton Density Fat Fraction data and R2\* data is supporting fat content ratio.
- EPI
  - **Exsper (Expanded SPEEDER):** This application allows reducing scan time for diffusion imaging. Exsper technique scans center of k-space data but surrounding area data is undersampled. It finds the coefficient from the data of center of k-space and synthesizes the undersampled data by using surrounding data and the coefficient.
- FFE 3D:
  - **Fast 3D for SSFP:** This application allows Fast 3D mode in SSFP 3D sequences, which helps to reduce the scan time by about 50 %.
- 3D Time-of-Flight (ToF):
  - **Fast 3D for TOF:** This application allows reducing the scan time while maintaining image quality by up to half for TOF images by adjusting data acquisition ratio.
- **Short T2\* map (multi echo-UTE):** UTE Imaging is available for acquisition of different TE data for T2\* mapping of tissues with short T2\*.
- **Advanced DWI-Diffusion time:** Various diffusion times are available
- **AiCE - noise estimation improvement:** By taking into consideration g-factor, noise can be removed from the part where g-factor was considered.

**19. SAFETY PARAMETERS**

Item	Subject Device: Vantage Galan 3T, MRT-3020, V7.0 with AiCE Reconstruction Processing Unit for MR	Predicate Device: Vantage Galan 3T, MRT-3020, V6.0 with AiCE Reconstruction Processing Unit for MR (K192574)	Notes
Static field strength	3T	3T	Same
Operational Modes	Normal and 1st Operating Mode	Normal and 1st Operating Mode	Same
i. Safety parameter display	SAR, dB/dt	SAR, dB/dt	Same
ii. Operating mode access requirements	Allows screen access to 1st level operating mode	Allows screen access to 1st level operating mode	Same
Maximum SAR	4W/kg for whole body (1st operating mode specified in IEC 60601-2-33: 2010+A1:2013+A2:2015)	4W/kg for whole body (1st operating mode specified in IEC 60601-2-33: 2010+A1:2013+A2:2015)	Same
Maximum dB/dt	1st operating mode specified in IEC 60601-2-33: 2010+A1:2013+A2:2015	1st operating mode specified in IEC 60601-2-33: 2010+A1:2013+A2:2015	Same
Potential emergency condition and means provided for shutdown	Shutdown by Emergency Ramp Down Unit for collision hazard for ferromagnetic objects	Shutdown by Emergency Ramp Down Unit for collision hazard for ferromagnetic objects	Same

**20. IMAGING PERFORMANCE PARAMETERS**

No change from the previous predicate submission, K192574.

**21. INDICATIONS FOR USE**

Vantage Galan 3T systems are indicated for use as a diagnostic imaging modality that produces cross-sectional transaxial, coronal, sagittal, and oblique images that display anatomic structures of the head or body. Additionally, this system is capable of non-contrast enhanced imaging, such as MRA.

MRI (magnetic resonance imaging) images correspond to the spatial distribution of protons (hydrogen nuclei) that exhibit nuclear magnetic resonance (NMR). The NMR properties of body tissues and fluids are:

- Proton density (PD) (also called hydrogen density)
- Spin-lattice relaxation time (T1)
- Spin-spin relaxation time (T2)
- Flow dynamics
- Chemical Shift

Depending on the region of interest, contrast agents may be used. When interpreted by a trained physician, these images yield information that can be useful in diagnosis.

**22. SUMMARY OF DESIGN CONTROL ACTIVITIES**

Risk Management activities for new software functionalities and pulse sequences are included in this submission. The test methods used are the same as those submitted in the previously cleared submission of the predicate device, Vantage Galan 3T, MRT-3020, V6.0 with AiCE Reconstruction Processing Unit for MR (K192574). A declaration of conformity with design controls is included in this submission.

**23. SAFETY**

This device is designed and manufactured under the Quality System Regulations as outlined in 21 CFR § 820 and ISO 13485 Standards.

This device is based upon the same technologies, materials and software as the predicate device. Risk activities were conducted in concurrence with established medical device development standards and guidance. Additionally, testing was done in accordance with applicable recognized consensus standards published by the International Electrotechnical Commission (IEC) for medical devices and the National Electrical Manufacturers Association (NEMA):

**LIST OF APPLICABLE STANDARDS**

- ANSI AAMI ES60601-1:2005/(R)2012 and A1:2012
- IEC60601-1-2 (2014)
- IEC60601-1-6 (2010), Amd.1 (2013)
- IEC60601-2-33 (2010), Amd.1 (2013), Amd.2 (2015)
- IEC60825-1 (2007)
- IEC62304 (2006), Amd.1 (2015)
- IEC62366 (2007), Amd.1 (2014)
- NEMA MS 1 (2008)
- NEMA MS 2 (2008)
- NEMA MS 3 (2008)
- NEMA MS 4 (2010)
- NEMA MS 5 (2010)

**24. TESTING**

Risk analysis and verification/validation testing conducted through bench testing are included in this submission which demonstrate that the system requirements have been met. Additionally, image quality testing was completed which demonstrated that the subject device meets predetermined acceptance criteria.

MR image quality metrics were performed, utilizing volunteer images, to assess 3D FAST sequences and 3D Compressed SPEEDER acceleration sequences. Representative images, reviewed by American Board Certified Radiologists and American Board Certified Cardiologists with MR certification, were obtained using the subject device. Reviewers provided detailed assessments of overall image noise, image sharpness, image degradation, image artifacts, diagnostic confidence, contrast, lesion/pathology conspicuity, and clinical utility. It was confirmed that 3D FAST and 3D Compressed SPEEDER images were of diagnostic quality.

Software Documentation for a Moderate Level of Concern, per the FDA guidance document, "Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices Document" issued on May 11, 2005, is also included as part of this submission.



**25. SUBSTANTIAL EQUIVALENCE**

Canon Medical Systems Corporation believes that the Vantage Galan 3T, MRT-3020, V7.0, Magnetic Resonance Imaging (MRI) System with AiCE Reconstruction Processing Unit for MR is substantially equivalent to the previously cleared predicate device, Vantage Galan 3T, MRT-3020, V6.0 with AiCE Reconstruction Processing Unit for MR, referenced in this submission. Canon Medical Systems Corporation believes that the changes incorporated into the Vantage Galan 3T, MRT-3020, V7.0 with AiCE Reconstruction Processing Unit for MR are substantially equivalent to the previously cleared predicate device.

**26. CONCLUSION**

The modifications incorporated into the Vantage Galan 3T, MRT-3020, V7.0 with AiCE Reconstruction Processing Unit for MR do not change the indications for use or the intended use of the device. Based upon bench testing, volunteer clinical imaging, successful completion of software validation and application of risk management and design controls, it is concluded that the subject device is safe and effective for its intended use.